145383-72-8Relevant articles and documents
PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS
-
Paragraph 00267-00268, (2018/05/27)
The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity Formula (I). The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
-
Page/Page column 78-79, (2010/12/29)
The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
Azoles. Part 10. Thiazolothienopyrimidine, a New Heterocyclic Ring System
Athmani, Salah,Iddon, Brian
, p. 7689 - 7702 (2007/10/02)
Thienothiazoles were prepared by reaction of 4-chlorothiazole-5-carbaldehydes or 4-chlorothiazole-5-carbonitriles with either ethyl 2-mercaptoacetate or 2-mercaptoacetamide.The 6-aminothienothiazole-5-carboxamides obtained were converted int
